DE60115349D1 - Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C) - Google Patents
Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)Info
- Publication number
- DE60115349D1 DE60115349D1 DE60115349T DE60115349T DE60115349D1 DE 60115349 D1 DE60115349 D1 DE 60115349D1 DE 60115349 T DE60115349 T DE 60115349T DE 60115349 T DE60115349 T DE 60115349T DE 60115349 D1 DE60115349 D1 DE 60115349D1
- Authority
- DE
- Germany
- Prior art keywords
- gene
- polymorphisms
- oatp
- organic anion
- oatpc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22690900P | 2000-08-23 | 2000-08-23 | |
US226909P | 2000-08-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60115349D1 true DE60115349D1 (de) | 2006-01-05 |
DE60115349T2 DE60115349T2 (de) | 2006-08-10 |
Family
ID=22850936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60115349T Expired - Lifetime DE60115349T2 (de) | 2000-08-23 | 2001-08-17 | Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C) |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020090622A1 (de) |
EP (2) | EP1589115A3 (de) |
JP (1) | JP2002330758A (de) |
AT (1) | ATE311476T1 (de) |
CY (1) | CY1106070T1 (de) |
DE (1) | DE60115349T2 (de) |
DK (1) | DK1186672T3 (de) |
ES (1) | ES2252159T3 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60042220D1 (de) | 1999-09-21 | 2009-06-25 | Chugai Pharmaceutical Co Ltd | Verwendung vom transportergen oatp-c zur screening von testsubstanzen |
GB0213580D0 (en) * | 2002-06-13 | 2002-07-24 | Astrazeneca Ab | Methods |
GB0317592D0 (en) * | 2003-07-26 | 2003-08-27 | Astrazeneca Ab | Method |
EP1784504A2 (de) * | 2004-07-21 | 2007-05-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | C463a-polymorphismus des oatp-c-gens als grundlage für das variable ansprechen auf die statintherapie |
FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
ES2744797T3 (es) | 2008-02-29 | 2020-02-26 | Univ Oxford Innovation Ltd | Procedimiento de determinación de una dosis adecuada de estatina |
US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
EP2267153A1 (de) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identifizierung der Netrin-1-Rezeptor-unc5c-Genmutation bei festen Krebsen |
US8765377B2 (en) | 2011-10-13 | 2014-07-01 | Boston Heart Diagnostics Corporation | Compositions and methods for treating and preventing coronary heart disease |
WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
EP3220810A4 (de) | 2014-11-17 | 2018-05-16 | Boston Heart Diagnostic Corporation | Beurteilung des risikos für herz-kreislauf-erkrankungen |
JP7067896B2 (ja) * | 2017-10-27 | 2022-05-16 | シスメックス株式会社 | 品質評価方法、品質評価装置、プログラム、および記録媒体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
AU5340699A (en) * | 1998-08-07 | 2000-02-28 | Axys Pharmaceuticals, Inc. | Human anion transporter genes atnov |
-
2001
- 2001-08-10 US US09/925,731 patent/US20020090622A1/en not_active Abandoned
- 2001-08-17 DK DK01306983T patent/DK1186672T3/da active
- 2001-08-17 AT AT01306983T patent/ATE311476T1/de active
- 2001-08-17 ES ES01306983T patent/ES2252159T3/es not_active Expired - Lifetime
- 2001-08-17 DE DE60115349T patent/DE60115349T2/de not_active Expired - Lifetime
- 2001-08-17 EP EP05011183A patent/EP1589115A3/de not_active Withdrawn
- 2001-08-17 EP EP01306983A patent/EP1186672B1/de not_active Expired - Lifetime
- 2001-08-22 JP JP2001251461A patent/JP2002330758A/ja active Pending
-
2003
- 2003-10-31 US US10/698,808 patent/US20040235006A1/en not_active Abandoned
-
2006
- 2006-02-28 CY CY20061100280T patent/CY1106070T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1186672B1 (de) | 2005-11-30 |
DE60115349T2 (de) | 2006-08-10 |
US20040235006A1 (en) | 2004-11-25 |
EP1589115A3 (de) | 2006-05-31 |
CY1106070T1 (el) | 2011-06-08 |
EP1186672A2 (de) | 2002-03-13 |
US20020090622A1 (en) | 2002-07-11 |
EP1589115A2 (de) | 2005-10-26 |
DK1186672T3 (da) | 2006-03-06 |
ES2252159T3 (es) | 2006-05-16 |
ATE311476T1 (de) | 2005-12-15 |
EP1186672A3 (de) | 2002-09-25 |
JP2002330758A (ja) | 2002-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106070T1 (el) | Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene) | |
IL225203A (en) | An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity | |
IL153052A0 (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
IL176674A0 (en) | Fc region variants | |
NO20053855L (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
NO20070049L (no) | Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese | |
ATE462702T1 (de) | Für die behandlung von entzündlichen krankheiten nützliche beta-carboline | |
DK1560812T3 (da) | Aminocyclohexyletherforbindelser og anvendelser deraf | |
NO20055741D0 (no) | Nye kjemiske forbindelser | |
DE60235005D1 (de) | Nachweis der instabilität von mikrosatelliten und | |
DE60313004D1 (de) | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination | |
PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
ATE495193T1 (de) | Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist | |
EP1469084A3 (de) | Polymorphismen im menschlichen KDR Gene | |
BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
EP2096120A3 (de) | Verwendung sekretierter Proteinprodukte zur Prävention und Behandlung von Erkrankungen der Bauchspeicheldrüse und/oder Adipositas und/oder des metabolischen Syndroms | |
EP1130122A3 (de) | Methode zur Detektion von Polymorphismen des humanen EP1-R Gens | |
WO2002072632A3 (en) | Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof. | |
EP1184465A3 (de) | Verfahren zur Diagnose von Polymorphismen des humanen MCT-1 Gens sowie hierdurch definierte Wirkstoffe | |
WO2002068687A3 (en) | Function and application of tob gene in central nervous system of mammal | |
DE60222669D1 (de) | Asthma-assoziiertes gen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |